Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATReceivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Cardiol Therapeutics (CRDL) Shares Issued (2020 - 2026)

Cardiol Therapeutics filings provide 1 years of Shares Issued readings, the most recent being $64.5 million for Q4 2021.

  • On a quarterly basis, Shares Issued changed N/A to $64.5 million in Q4 2021 year-over-year; TTM through Dec 2021 was $66.7 million, a N/A change, with the full-year FY2025 number at $24520.6, down 81.09% from a year prior.
  • Shares Issued hit $64.5 million in Q4 2021 for Cardiol Therapeutics, up from $102346.9 in the prior quarter.
  • In the past five years, Shares Issued ranged from a high of $64.5 million in Q4 2021 to a low of $84281.4 in Q2 2021.